胡适 教授

第二军医大学基础医学部

胡适，男，第二军医大学基础医学院教授，硕士生导师。研究方向为抗体药物工程和新型细胞治疗技术。现主持国家自然科学基金新型冠状病毒专项、面上项目、重大新药创制子课题等十余项各类科研项目。近五年内以通讯作者在Science Translational Medicine，Nature Communications、Clinical Cancer Research等国际刊物上发表SCI论文二十余篇，申请中国专利19项，PCT专利8项。主要研究方向包括新型抗体工程技术和细胞治疗技术的应用研究。

代表论著：

(1) Shi Hu^†*, Wenyan Fu^†, Tian Li, Ying Tang, Qingning Yuan, FeifeiWang, Gaojian Lv, Yuanyuan Lv, Xiaoyan Fan, Sheng Zhang, Ruobing Jin, Yafeng Shen, Fangxing Lin, Xuting Ye, Yongji Yang, and Changhai Lei*. Antagonism of EGFR and Notch Limits Acquired Resistance to EGFR Inhibitors and Radiation by Decreasing Tumor-Initiating Cell Frequency. Science Translation Medicine, 2017. 9(380): p. eaag0339.

(2) Shi Hu^†*, Wenyan Fu^†, Weihao Xu^†, Yang Yang, Melissa Cruz, Sandra D Berezov, Daniel Jorissen, Hiroaki Takeda, and Wangdong Zhu*, Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer research, 2015. 75(1): p. 159-170.

(3) Shi Hu^†*, Haibin Dai^†, Tian Li^†, Ying Tang, Wenyan Fu, Qingning Yuan, FeifeiWang, Gaojian Lv, Yuanyuan Lv, Xiaoyan Fan, Sheng Zhang, Ruobing Jin, Yafeng Shen, Fangxing Lin, Xuting Ye, Min Ding, Yongji Yang, and Changhai Lei*. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. Cancer Letters, 2016, 382(1): 32-43.

(4) Shi Hu^†, Shuaiyi Liang^†, Huaizu Guo, Dapeng Zhang, Hui Li, Xiaoze Wang, Weili Yang, Weizhu Qian, Sheng Hou, Hao Wang, Yajun Guo*, and Zhiyong Lou*, Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View. Journal of Biological Chemistry, 2013. 288(38): p. 27059-27067.